SEC Filing: Form 4
Statement of changes in beneficial ownership of securities
VYNE TherapeuticsRooted in Innovation
VYNE Therapeutics
Statement of changes in beneficial ownership of securities
Statement of changes in beneficial ownership of securities
VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target engagement and inflammatory biomarkers Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single ascending dose (“SAD”) portion of its ongoing Phase 1a trial of VYN202. The…
Current report
BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced that management will participate in two investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024, New York, NY Format: One-on-one investor meetings Stifel 2024 Virtual Immunology and Inflammation Summit September 17-18, 2024 Presentation: Tuesday, September 17, 2024 at 8:30 AM ET Format: Fireside Chat and one-on-one investor meetings Registration: Webcast link A webcast replay will be available on…
Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025 Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected in Q3 and Q4 2024, respectively Balance sheet expected to fund key clinical milestones for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the…